Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.5% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 30,946 shares of the life sciences company’s stock after purchasing an additional 755 shares during the quarter. Wellington Management Group LLP’s holdings in Illumina were worth $4,036,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Bank of New York Mellon Corp raised its stake in shares of Illumina by 7.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company’s stock worth $317,267,000 after buying an additional 204,043 shares during the last quarter. Primecap Management Co. CA increased its holdings in Illumina by 3.6% during the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock valued at $328,158,000 after acquiring an additional 87,599 shares in the last quarter. Janus Henderson Group PLC raised its position in Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after acquiring an additional 625,245 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Illumina by 305.0% in the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock valued at $155,067,000 after purchasing an additional 1,118,747 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Illumina by 4.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock valued at $164,334,000 after purchasing an additional 54,319 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Piper Sandler reduced their price objective on Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. JPMorgan Chase & Co. lifted their price target on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Barclays upped their price objective on shares of Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Argus raised shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 target price for the company in a research note on Wednesday, August 28th. Finally, Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price target on the stock in a research note on Thursday, October 17th. Eight investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Illumina has a consensus rating of “Moderate Buy” and a consensus target price of $165.95.

Illumina Price Performance

Illumina stock opened at $143.12 on Wednesday. The firm has a fifty day moving average of $144.42 and a 200-day moving average of $129.20. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $22.70 billion, a P/E ratio of -14.37 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same period in the prior year, the firm earned $0.33 EPS. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. As a group, analysts predict that Illumina, Inc. will post 4.11 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.